PPD Pharmaceutical Development(Beijing)Co., Ltd.

To evaluate the long-term safety and tolerability of KarXT in subjects with AD-related psychiatric and behavioral symptoms

Primary objective: ● To evaluate the effectiveness of KarXT compared with placebo in treating subjects with AD-related psychiatric and behavioral symptoms based on the Neuropsychiatric Inventory-Clinician Rating Scale (NPI-C): Hallucinations and Delusions (H+D) scores Key secondary objectives: ● To evaluate the effectiveness of KarXT compared with placebo in treating agitation in subjects with AD-related psychiatric and behavioral symptoms based on the Cohen-Mansfield Agitation Inventory (CMAI) scores Other secondary objectives: ● To evaluate the effectiveness of KarXT compared with placebo using the following indicators: - The overall severity of the disease was assessed using the Clinical Global Impression-Severity (CGI-S) scale. CGI-S requires assessors to consider various aspects of psychosis (hallucinations and delusions) before making an overall assessment of severity - NPI-C Core Score: Hallucinations, Delusions, Agitation, and Aggression Dimensions, NPI-C: Agitation Score NPI-C Core Score: Caregiver Distress Scale (Hallucinations, Delusions, Agitation, and Aggression Dimensions) - Responsiveness (responders were defined as those with an improvement of ≥40% in NPI-C: H+D [hallucinations and delusions] scores) Safety Objectives: ● To evaluate the safety and tolerability of KarXT compared to placebo in subjects with psychiatric and behavioral symptoms associated with AD

Compare the efficacy of redasemtide with placebo Assess the safety and tolerability of redasemtide